Teva to present data on MS program at joint ECTRIMS/ACTRIMS congress
Teva Pharmaceutical Industries announced that new data on its multiple sclerosis program, including COPAXONE, a product for relapsing forms of MS, and laquinimod, an investigational MS therapy, will be highlighted in 11 presentations at the 7th Joint Congress of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple Sclerosis in Paris, October 25-28, 2017. In addition to the data being presented, Teva will also host a Satellite Symposium, "Maintaining ability in the context of disability: can we do more for patients?" on October 27, 2017 from 12:45 - 1:45 p.m. CET. COPAXONE is indicated for the treatment of patients with relapsing forms of multiple sclerosis. The most common side effects of COPAXONE are redness, pain, swelling, itching, or a lump at the site of injection, flushing, rash, shortness of breath, and chest pain. COPAXONE is rated as Pregnancy Category B. There are no adequate and well-controlled studies in pregnant women. Administration of glatiramer acetate by subcutaneous injection to pregnant rats and rabbits resulted in no adverse effects on offspring development.